Drugs / PF-4191834
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01147458 | Jul 2010 → Feb 2011 | osteoarthritis, knee | Pfizer | Terminated | Missed primary |
| Phase 2 | NCT00723021 | Jul → Dec 2008 | asthma | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01265732 Comparator | Dec 2010 → Jan 2011 | — | Pfizer | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-4191834 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297416 ↗ |
| Known as | PF-04191834 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00723021 ↗ |
| Action | Inhibit | “PF-04191834 works in animal models by inhibiting one of the enzymes, 5-lipoxygenase” NCT01147458 ↗1“Arachidonate 5-lipoxygenase inhibitor” CHEMBL4297416 ↗ |
| Modality | Small molecule | — CHEMBL4297416 ↗ |
| Route | Oral | “oral dispersion” NCT00723021 ↗ |
| Target | ALOX5 | “Arachidonate 5-lipoxygenase inhibitor” CHEMBL4297416 ↗ |